Table 2.

Progression during durvalumab maintenance and its treatment

Stage	T-Stage	N-Stage	Histology	PD-L1%	Site of Progression	Progression months after TRT	Cylcles of durva-lumab applied	Months of durvalumab treatment	Oligo-progression	Therapy after progression
IIIC	3	3	AC	1	DM multi	2.7	6	2.2	no	Docetaxel + Nintedanib
IIIC	4	3	AC	90	DM bone	3.6	7	2.8	no	Carboplatin + Pemetrexed
IIIB	4	2	NOS	30	DM bone	5.7	7	4.1	yes	palliative radiotherapy (10x 3Gy)
IIIB	2	3	SCC	80	DM sing. Bone	5.1	10	4.1	yes	SABR (10 x 4Gy) + continuation of durvalumab treatment
IIIA	2	2	AC	30	BM	7.9	14	6.1	yes	stereotactic radiosurgery (SRS, 20Gy Iso 80%)
IIIA	1	2	AC	15	LRR	8.1	14	6.7	yes	RET-TKI (LOXO-292)
IIIB	3	2	AC	40	BM	11.0	15	8.7	yes	surgery + radiotherapy (SRS, 5x 5Gy Iso 80%)
IIIB	4	2	SCC	90	LRR	14.0	17	11.3	yes	re-radiotherapy with SABR (10x 4Gy)